Can a Combination of AT1R Antagonist and Vitamin D Treat the Lung Complication of COVID-19?
Am J Med Sci
; 360(4): 338-341, 2020 10.
Article
in English
| MEDLINE | ID: covidwho-650676
ABSTRACT
Severe Acute Respiratory Distress Syndrome caused by a novel human coronavirus SARS-CoV-2 named COVID-19 and declared as a pandemic. This paper reviews the possibility of repurposing angiotensin type 1 receptor (AT1R) antagonists and vitamin D to treat COVID-19. ACE2 protein found on the cell membranes is the target of SARS-CoV-2 for entering into the host cells. Viral spike protein-binding with ACE2 down-regulates it. As ACE2 is known to protect the lung from injuries, SARS-CoV-2-induced ACE2 deficiency may expose patients to lung damage. AT1R antagonists and vitamin D increase the expression of ACE2 independently. Besides, vitamin D suppresses the compensatory increase in renin levels following the inhibition of the renin-angiotensin system by AT1R antagonists. Therefore, a combination of AT1R antagonists and vitamin D may offer protection against COVID-19 induced lung injury.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Vitamin D
/
Vitamins
/
Coronavirus Infections
/
Severe Acute Respiratory Syndrome
/
Angiotensin II Type 1 Receptor Blockers
Topics:
Long Covid
Limits:
Animals
/
Humans
Language:
English
Journal:
Am J Med Sci
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS